Amivantamab, an EGFR‐MET bispecific antibody, and mobocertinib, an ex20ins‐specific TKI, were recently approved by the FDA (and also the EMA for amivantamab) for the treatment of patients with EGFR ex20ins NSCLC, as detected by an FDA‐approved test, whose disease progressed on or following platinum‐based chemotherapy [9, 10, 11, 12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.